Eli Lilly Posts Blowout Q3, Raises 2025 Outlook

Eli Lilly reported Q3 revenue of $17.60 billion (about +54% year‑over‑year) and non‑GAAP EPS of $7.02, sending shares up roughly 5–7% in premarket trading. The beat was driven by GLP‑1 medicines—Mounjaro generated about $6.52 billion (+109%) and Zepbound roughly $3.57–3.59 billion (+~184–185%)—with volumes rising sharply even as realized prices softened. Lilly raised full‑year 2025 guidance to $63.0–63.5 billion in revenue and $23.00–23.70 in adjusted EPS. The company reported positive Phase 3 results for oral obesity candidate orforglipron and said it plans regulatory submissions by year‑end while expanding manufacturing capacity. Lilly also struck distribution arrangements, including Walmart pickup for Zepbound. Analysts warned that pricing pressure, reimbursement dynamics and possible supply constraints could temper margins despite higher volumes.